3 / 3
Volume 09
Journal of Alzheimers Disease & Parkinsonism
ISSN: 2161-0460
Page 20
August 29-31, 2019 Vienna, Austria
&
5
th
International Conference on
Epilepsy & Treatment
5
th
World Congress on
Parkinsons & Huntington Disease
Epilepsy 2019
Parkinsons Congress 2019
August 29-31, 2019
JOINT EVENT
conference
series
.com
Sharon Ceanna Fernando, J Alzheimers Dis Parkinsonism 2019, Volume 09
Sharon Ceanna Fernando
Syneos Health, USA
Clinical surveillance to monitor and maximize efficacy in primary endpoints in epilepsy trials
E
pilepsy is a complex disorder, noted for its heterogeneous and unpredictable manifestation which can amplify
diagnostic uncertainty. This can be exacerbated by variability in access to diagnostic methods and site personnel
experience with various epileptic syndromes. Evenwhen the clinical diagnosis is accurate, seizure frequency is notoriously
difficult to measure reliably and evenmore problematic to assess in pediatric epilepsy trials. These concerns are intensified
when trials are performed on a global scale and across numerous study centers that conduct neurological clinical trials
in multiple indications. I will discuss how Syneos Health can help minimize the risk of these issues through the use of
our Clinical Surveillance and Training (CST) team. In addition, Syneos Health can offer additional value propositions
regarding the next stage in clinical development – commercialization. Research indicates that 75% of products across
various indications that reach the market are commercial failures because they lack integrated planning across the clinical
and commerical continuum. At Syneos Health-the industry’s only biopharma accelerator, we understand the worldwide
gold standard for solving intricate problems and optimizing opportunities, thereby ensuring that promising compounds
have the important support in order to make it to market. Clinical Surveillance & Training has over twenty years of
experience working in clinical trials and works to streamline efficiencies to address data impacting errors discovered
during seizure diary review processes, thereby helping to increase the likelihood of commercial success in Epilepsy Trials.
Biography
Sharon Fernando is a US trained clinical psychologist with extensive experience in Primary Care facilities, multidisciplinary practice and most recently with the
Industry’s only biopharma accelator. Dr. Fernando graduated with her Psy.D. from the Florida Institute of Technology with a specialization in pediatric clinical
psychology. Fernando has more than six years of experience with Syneos Health and her current role is as a Senior Clinical Scientist within CST. She provides
scientific oversight and clinical guidance for projects within CST and interacts with senior management, customers, and project teams to ensure scientific integrity
and data quality in clinical trials. Dr. Fernando is also called upon to provide scientific input as needed to projects outside CST and contribute to business
development activities with direct line management and mentoring responsibilities. Her therapeutic areas include CNS related studies.Having lived across three
continents, Dr. Fernando's intimate knowledge of interacting with diverse populations makes her especially well suited to understanding and respecting cross
cultural differences in clinical trials.